source
- iOnctura’s roginolisib shows encouraging phase 1 results in metastatic uveal melanomaiOnctura, a spinout of Merck KGaA, reported data from a two‑part phase 1 trial of its PI3K delta inhibitor roginolisib in patients with advanced solid and hematologic cancers, including a cohort of…
- Stryker invests $400 million in CMR Surgical, securing exclusive U.S. rights to Versius robotic platformStryker announced a strategic investment of about $400 million in UK‑based CMR Surgical, a developer of modular, portable surgical robots. Under the agreement, Stryker will act as the exclusive U.…